Literature DB >> 15064671

Assessment and management of patients with ischemic heart disease.

Shamsuddin Akhtar1, David G Silverman.   

Abstract

OBJECTIVE: Review the perioperative management of patients who are scheduled for noncardiac surgery. DATA SOURCE: Review of literature (PubMed, MEDLINE).
CONCLUSIONS: Patients with ischemic heart disease who undergo noncardiac surgery are at significant risk of perioperative cardiac morbidity and mortality. Recent joint guidelines from the American College of Cardiology and American Heart Association have significantly streamlined the preoperative evaluation processes. Augmented hemodynamic control with intensive perioperative pharmacologic therapy with beta-blockers and possibly alpha-2 agonist has been shown to improve perioperative cardiovascular outcomes. However, translating this information to clinical practice continues to be a challenge and requires a multi- disciplinary approach. A particular intraoperative anesthetic technique is unlikely to influence perioperative cardiac morbidity and mortality. Postoperative management with goals of decreasing hemodynamic stress is important in patients with ischemic heart disease. Diagnosis and management of perioperative myocardial infarction continues to be a challenge. However, use of cardiac specific biomarkers should improve the diagnostic process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064671     DOI: 10.1097/01.ccm.0000121576.73871.2d

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  2 in total

Review 1.  Preoperative evaluation and a risk assessment in patients undergoing abdominal surgery.

Authors:  Siyamek Neragi-Miandoab; Michael Wayne; Michael Cioroiu; Lee M Zank; Christopher Mills
Journal:  Surg Today       Date:  2010-01-28       Impact factor: 2.549

Review 2.  Significance and interpretation of elevated troponin in septic patients.

Authors:  Raphael Favory; Remi Neviere
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.